



Recent Advances in Chronic Rhinosinusitis and Asthma

Guest Editors:

Dr. Giuseppe Guida

1. Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy
2. Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Orbassano, 10043 Turin, Italy

Dr. Cristiano Caruso

Department of di Medical and Surgical Science, Fondation Universitary Policlinic A. Gemelli IRCCS, University Cattolica Sacro Cuore, 20123 Rome, Italy

Deadline for manuscript submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

Asthma and chronic rhinosinusitis (CRS) are often clinically associated, and they reciprocally influence prognosis and outcome. The basis of this close relationship is found in their common immunopathology. Nowadays, both asthma and CRS are classified into different phenotypes, with the main defined as a Type-2 inflammatory disease. Nasal polyps are one of the main clues for a Type-2 phenotype. This phenotype is characterized by epithelial barrier dysfunction; activation of Type-2 immune cells, including T helper 2 lymphocytes, dendritic cells, innate lymphoid cells Type-2, eosinophils, and mast cells; and imbalance at the host airway–microbial interface. The Type-2 low phenotypes are less understood but often represent clinical challenges due to their low response to medical treatment. The era of precision medicine led to pharmacological interventions able to modulate a specific immunological Type-2 pathway and provided clinical significant benefits. The aim of this Special Issue is to document new advances in the field of asthma and CRS immunopathogenesis through original articles and reviews.

Dr. Giuseppe Guida
Dr. Cristiano Caruso
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)